However, Wang-Yu et al. [10] reported that 56 patients with MLL-r AML (10 children and 46 adults) who received allo-HSCT had a 3-year OS of 61.8%; the adults and children had comparable OSs and leukaemia-free survivals. The gene discussed is KMT2A; the disease is leukemia.